Adalimumab biosimilar - EMD Serono/Merck

Drug Profile

Adalimumab biosimilar - EMD Serono/Merck

Alternative Names: MSB-11022

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator EMD Serono
  • Developer EMD Serono; Merck KGaA
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis
  • Research Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 15 Nov 2016 Phase-III clinical trials in Rheumatoid arthritis (Treatment-experienced) in Hungary (SC) (EudraCT2016-002852-26)
  • 01 Feb 2016 Phase-III clinical trials in Plaque psoriasis (Treatment-experienced) in United Kingdom, Russia, Poland, Mexico, Hungary, Hungary, France, Estonia, Czech Republic, Canada, Bulgaria, USA (SC) after February 2016 (NCT02660580)
  • 01 Feb 2016 Phase-III clinical trials in Plaque psoriasis (Treatment-experienced) in Germany (SC) (NCT02660580)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top